Nowadays, the improvement of the cardiorenal prognosis in patients with type 2 diabetes is largely independent of the current metabolic situation. The focus of patient-oriented treatment is on quality of life and organ protection. This is reflected in the current recommendations of the European and US diabetes societies (EASD/ADA) and in the practical recommendations of the German Diabetes Association (DDG). In addition, the European Society of Cardiology (ESC) has published evidence-based guidelines for the cardiorenal management of type 2 diabetics.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- SwissDiab Study: New Analysis Published
How are diabetes complications associated with quality of life?
- Pre-acclimatization on Mount Everest
Exploring the physiological limits
- Viloxazine for ADHD
A non-stimulating option—but with limited evidence
- Preclinical study on phytotherapeutic agent
Active ingredient combination of peppermint and caraway oil modified fecal microbiota
- Casuistry
Rituximab used effectively against IgG4-RD colitis
- Sarcoidosis
New options from JAKi to mTOR
- Head and neck squamous cell carcinoma
Precision immunotherapy and local treatment
- From symptom to diagnosis